Kellner Group says former AIM ImmunoTech executive supports nominees

Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert Chioini and Paul Sweeney issued a press release in connection with their “efforts to bring accountability to the entrenched, incumbent” Board of Directors of AIM Immunotech (AIM). The group said, ” Wayne Springate, a former Senior Vice President and officer of AIM, is publicly declaring his support for the changes in leadership and voting for all of the Kellner Group Nominees on the Gold proxy card in the ongoing proxy contest. Mr. Springate served as an officer and held various leadership positions at AIM for eighteen years, from 2002 through 2020, most recently as Vice President of Special Projects. With decades of experience in the biopharma/health care sector, Springate remains committed to advancing innovative solutions and advocating for value creation in the Healthcare industry. Mr. Springate is the second former AIM executive to support the Kellner Group’s efforts in the past week, following the announcement that Ampligen co-founder and former AIM CEO Dr. Carter agreed to join the Scientific Advisory Board if the Kellner Group Nominees are elected.” “I strongly support the necessary change in board composition and believe that each of the Kellner Group Nominees can work together to drive significant change at AIM and create value for stockholders,” said Springate. “Having been with AIM for many years, holding senior positions, I had firsthand experience with the company’s incredible potential. When I left over three years ago, AIM was well-positioned for success. The company had the opportunity to advance its clinical studies, manufacture Ampligen and Alferon at its state-of-the-art facility in New Brunswick, and drive shareholder value. I believe the Kellner Group Nominees can lead AIM to finally realizing its great potential. The Kellner Group’s proposals offer the opportunity for fresh perspectives, expertise, and a clear vision to turn AIM around. It’s time to bring in new leadership that prioritizes shareholders and the future of Ampligen.”